Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05439135

Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract

This is a prospective, randomized, multicenter study to evaluate WMT in improving nutritional status in malnourished patients who underwent nonphysiological reconstruction of the upper gastrointestinal tract. In this multicenter trial, sixty-two patients will be enrolled in forteen Chinese sites. Participants will be randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic TET. After WMT, each participant will receive free diet plus home enteral nutrition. Home enteral nutrition should last for 2 months at home, with blood, urine and stool samples taken and stored at baseline and 2 months after WMT.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210000, China

Location status: Recruiting

Location contact

Faming Zhang

CONTACT

[email protected]

+86-25-56662093

About this study

Background: Malnutrition is a common complication of nonphysiological reconstruction of the upper gastrointestinal tract. The potential of washed microbiota transplantation (WMT) in improving nutritional status have been reported. The surgery procedure alters the anatomy and physiology of the digestive tract, which might impact the efficacy and safety of WMT when choosing different delivery way. This study aims to explore the optimal delivery of WMT in malnourished patients after rerouting of the upper gastrointestinal tract.

Methods and design: This multicenter, open-label, and randomized controlled trial will be conducted at forteen hospitals in China. Enteral nutrition (EN) will be administrated at enrollment. Participants will be then randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic transendoscopic enteral tubing (TET). Then the patients will receive free diet coupled with home enteral nutrition (HEN) for 8 weeks in both groups, with blood, urine and stool samples taken and stored at baseline and 2 months after WMT. The observation duration is 8 weeks. The primary endpoint is nutritional status of the patients. The nutritional status data obtained at baseline and 8 weeks after discharge includes body mass index (BMI) and skeletal muscle index (SMI). The secondary endpoints are nutritional assessment, nutrition-based laboratory indices, 60-day readmission rate, quality of life, gastrointestinal symptom scale, the safety of WMT and further analysis of the biological specimens.

Conclusion: It is estimated that WMT would help improve nutrition status. Moreover, this trial has the potential to identify the optimal delivery of WMT for patients undergoing nonphysiological reconstruction of the upper gastrointestinal tract.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergone nonphysiological reconstruction of the gastrointestinal tract (such as Billroth-II, Roux-en-Y, Child, Whipple reconstruction)
  • Aged over 18 years old;
  • Malnutrition is assessed by Nutritional Risk Screening 2002 score≥3 and Patient Generated Subjective Global Assessment (PG-SGA) score≥4;
  • Written informed consent;

Exclusion criteria

  • Expected survival time < 3 months;
  • Still on anti-tumor therapy or it is expected during the visit;
  • Complicated with ascites or edema caused by malnutrition;
  • Known organic gastrointestinal disease (e.g., gastrointestinal infection, inflammatory bowel disease, or radiation enteritis);
  • Undergone other gastrointestinal surgery (e.g., enterectomy, enterostomy, or gastrostomy) except appendectomy or anal fistula surgery;
  • Complicated with contraindications of enteral nutrition such as ileus, active gastrointestinal bleeding, and shock;
  • Cannot tolerate gastroscopy or colonoscopy;
  • Severe comorbidities (e.g., diabetes, cardiopulmonary failure, severe liver or or kidney diseases);
  • Complicated with other wasting diseases (e.g., active tuberculosis, hyperthyroidism, diabetes, HIV, active hepatitis, hip fracture, craniocerebral injury, etc.);
  • A history of anti-infective treatment within 30 days before enrollment; or need anti-infective treatment at the time of enrollment; or unwilling to stop taking drugs that affect gut microbes, such as probiotics;
  • Can not tolerate oral enteral nutrition;
  • Women who are pregnant or breastfeeding;
  • Participating in another clinical trial;
  • Deemed unsuitable for inclusion by the investigators.

Treatment and study plan

washed microbiota transplantation

Other

Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.

Other names: home enteral nutrition

Primary outcomes

  1. Changes of weight and height

    Time frame: baseline, 8 weeks post transplantation

    Weight and height will be combined to report BMI in kg/m^2.

  2. Changes of the third lumbar vertebrae skeletal muscle mass and height

    Time frame: baseline, 8 weeks post transplantation

    The third lumbar vertebrae skeletal muscle mass represents the sum of the cross-sectional areas of the skeletal muscles at the L3 level, including the psoas major, the erector spinae, the quadratus lumborum, the musculus transversus abdominis, the obliquus externus abdominis and the obliquus internus abdominis. Skeletal muscle mass and height will be combined to report the third lumbar vertebrae skeletal muscle mass index(L3 SMI) in cm^2/m^2.

  3. Changes of weight

    Time frame: baseline, 8 weeks post transplantation

Secondary outcomes

  1. Changes of Patient-Generated Subjective Global Assessment (PG-SGA)

    Time frame: baseline, 8 weeks post transplantation

    Patient-Generated Subjective Global Assessment (PG-SGA) includes patient-generated historical components (Weight History, Food Intake, Symptoms and Activities and Function) and the professional part (Diagnosis, Age, Metabolic stress, and Physical Exam).

  2. Changes of the Gastrointestinal Symptom Rating Scale(GSRS)

    Time frame: baseline, 4 weeks, 8 weeks post transplantation

    GSRS is a 13-item test to make a comprehensive assessment of common gastrointestinal symptom and each item receives a value from 0 to 3, with higher value indicating worse gastrointestinal condition.

  3. 60-day readmission rate

    Time frame: From enrollment to the end of treatment at 8 weeks

    The 60-day readmission is recorded and defined as nonelective readmission within 60 days after the treatment.

  4. The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0

    Time frame: From enrollment to the end of treatment at 8 weeks

    The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).

  5. Changes of the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L)

    Time frame: baseline, 4 weeks, 8 weeks post transplantation

    EQ-5D-5L is a 5-dimension questionnaire measuring health state and each dimension represents the level from 1 to 5, with higher level indicating worse health state.

  6. Changes of the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: baseline, 4 weeks, 8 weeks post transplantation

    PSQI is a self-rated questionnaire which assesses sleep quality over a 1-month time interval. Nineteen items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for seven components yields one global score, with higher score indicating worse sleep quality.

  7. Changes of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    Time frame: baseline, 4 weeks, 8 weeks post transplantation

    FACIT-Fatigue is a 13-item test measuring fatigue and each item receives a value from 0 to 4, with higher value indicating worse fatigue state.

  8. The difference of the gut microbiota composition before and after washed microbiota transplantation

    Time frame: baseline, 8 weeks post transplantation

    The composition of the gut microbiota is evaluated by sequencing faecal metagenome. We evaluate the differences in the structure of the flora and its metabolism.

  9. Change of insulin-like growth factor I(IGF-I)

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for Insulin-like growth factor I.

  10. Changes of hemoglobin

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for hemoglobin

  11. Changes of albumin

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for albumin

  12. Changes of prealbumin

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for prealbumin

  13. Changes of cholesterol

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for cholesterol

  14. Changes of transferrin

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for transferrin

  15. Changes of C-reactive protein

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for C-reactive protein

  16. Changes of full spectrum of bile acidsare

    Time frame: baseline, 8 weeks post transplantation

    Blood is tested for full spectrum of bile acidsare, including Cholic acid, deoxycholic acid, chenodeoxycholic acid, urs/hyodeoxycholic acid, lithocholic acid, glycocholic acid, glycolithocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, glycouran Deoxycholic acid, taurocholic acid, taurolithocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid.

  17. Changes of glucose breath testing

    Time frame: baseline, 8 weeks post transplantation

    A baseline breath sample was obtained, patients drank 50g glucose dissolved in 8 ounces of water, and breath samples were obtained at 15-minute intervals for 2 hours. Samples were analyzed to calculate breath H2 and/or breath CH4.

Sponsors and collaborators

Lead sponsor

The Second Hospital of Nanjing Medical University

Other

Collaborators

  • Armed Police Characteristic Medical Center
  • Beijing Rectum Hospital
  • Dazhou Central Hospital
  • First Affiliated Hospital Xi'an Jiaotong University
  • Guangzhou First People Hospital of Guangzhou Medical University
  • Hubei Hospital of Traditional Chinese Medicine
  • Hunan Aerospace Hospital
  • Huzhou Central Hospital
  • Jiamusi City Hospital of Traditional Chinese Medicine
  • Jiangxi University of Chinese Medicine Affiliated Hospital
  • Jingxing xian yiyuan
  • LanZhou University
  • Nanjing Medical University
  • PLA No. 901 Hospital of the Joint Support Force
  • Second Affiliated Hospital of Guangzhou Medical University
  • TAIHE country people's hospital
  • Tailai County People's Hospital
  • Tang-Du Hospital
  • The Affiliated Hospital Of Southwest Medical University
  • The Affiliated People's Hospital of Ningbo University
  • The First Affiliated Hospital of Anhui University of Chinese Medicine
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • The First People's Hospital of Kunshan
  • The Second Affiliated Hospital of Dalian Medical University
  • West China Fourth Hospital
  • Wuxi No. 2 People's Hospital
  • YI'AN PEOPLE'S HOSPITAL

Registry information

Official study title

An Open-label, Multicenter, Randomized Clinical Trial for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract: Washed Microbiota Transplantation Via Mid-gut Tube Versus Colonic Transendoscopic Enteral Tube

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 30, 2022
Registry last updated
Jul 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.